title: Synergistic activity of the Src/Abl inhibitor bosutinib in combination with imatinib.
authors.forename: S
authors.initials: S
authors.lastname: Redaelli
authors.forename: F
authors.initials: F
authors.lastname: Boschelli
authors.forename: P
authors.initials: P
authors.lastname: Perini
authors.forename: A
authors.initials: A
authors.lastname: Pirola
authors.forename: M
authors.initials: M
authors.lastname: Viltadi
authors.forename: C
authors.initials: C
authors.lastname: Gambacorti-Passerini
mesh_terms: D000814:Aniline Compounds / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides; D049109:Cell Proliferation / Q000187:drug effects*; D004357:Drug Synergism; D016044:Fusion Proteins, bcr-abl / Q000037:antagonists & inhibitors; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology*; D009570:Nitriles / Q000627:therapeutic use*; D010879:Piperazines / Q000627:therapeutic use*; D016315:Proto-Oncogene Proteins c-abl / Q000037:antagonists & inhibitors; D011743:Pyrimidines / Q000627:therapeutic use*; D011804:Quinolines / Q000627:therapeutic use*; D014407:Tumor Cells, Cultured; D019061:src-Family Kinases / Q000037:antagonists & inhibitors
chemical_list: D000814:Aniline Compounds; D000970:Antineoplastic Agents; D001549:Benzamides; D009570:Nitriles; D010879:Piperazines; D011743:Pyrimidines; D011804:Quinolines; C471992:bosutinib; D000068877:Imatinib Mesylate; D016044:Fusion Proteins, bcr-abl; D016315:Proto-Oncogene Proteins c-abl; D019061:src-Family Kinases